Image Place holder

Nainesh S. Parikh, MD, MBA


Specialty: Interventional Radiology
Program: Diagnostic Imaging and Interventional Radiology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Types Treated: Kidney (Renal Cell) Cancer , Liver Cancer , Oral Cavity or Throat Cancer , Penile Cancer, Prostate Cancer , Testicular Cancer , Throat Cancer, Tongue Cancer, Bladder Cancer , Head and Neck Cancer

Dr. Parikh’s clinical interests include treating patients with advanced malignancy utilizing minimally invasive techniques. Specific areas of interest include liver directed therapy for primary and secondary liver cancer, as well as for primary kidney cancer. Additionally, Dr. Parikh is interested in treating malignant and non-malignant tumors within the GU system, such as prostate cancer and benign prostatic hyperplasia, respectively. Dr. Parikh earned his undergraduate degree from Columbia University in New York City, and subsequently worked as an investment banker after graduation. After deciding that he wanted to have a significant impact on the daily lives of patients, he obtained MD and MBA degrees from Tufts University School of Medicine in Boston, MA. He then completed diagnostic radiology residency at NYU Medical Center in New York City, before moving back to Boston to complete a fellowship in Angiography and Interventional Radiology at the Brigham and Women’s Hospital – Harvard Medical School.

Education & Training

Board Certification:

  • Diagnostic Radiology
  • Vascular & Interventional Radiology

Fellowship:

  • NYU Medical Center - Body MR
  • Brigham and Women's Hospital/Harvard Medical School - Angiography and Interventional Radiology

Residency:

  • NYU Medical Center - Diagnostic Radiology

Medical School:

  • Tufts University School of Medicine - MD/MBA
Participating Trials

CLINICAL TRIAL 18119
A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Condition: Sarcoma
Intervention: Atezolizumab (Tecentriq); G100; G305; LV305; cyclophosphamide; cytoxan (cyclophosphamide)
Open

CLINICAL TRIAL 19480
The Reveal Study: A Phase 1/2, Open-Label, Multicenter, Dose Escalation And Dose Expansion Study Of Nktr-262 In Combination With Nktr-214 And In combination With Nktr-214 Plus Nivolumab In Patients With Locally Advanced Or Metastatic Solid Tumor Malignancies
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); NKTR-214; NKTR-262; Nivolumab
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Gangi A, Shah J, Hatfield N, Smith J, Sweeney J, Choi J, El-Haddad G, Biebel B, Parikh N, Arslan B, Hoffe SE, Frakes JM, Springett GM, Anaya DA, Malafa M, Chen DT, Chen Y, Kim RD, Shridhar R, Kis B. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study. J Vasc Interv Radiol. 2018 Aug;29(8):1101-1108. Pubmedid: 30042074.
  • Sweeney J, Parikh N. Inferior vena cava filter placement in a left IVC and drainage into duplicated SVC via hemiazygous continuation. Radiol Case Rep. 2018 Apr;13(2):320-323. Pubmedid: 29904464. Pmcid: PMC5999865.
  • Ream JM, Doshi AM, Dunst D, Parikh N, Kong MX, Babb JS, Taneja SS, Rosenkrantz AB. Dynamic contrast-enhanced MRI of the prostate: An intraindividual assessment of the effect of temporal resolution on qualitative detection and quantitative analysis of histopathologically proven prostate cancer. J Magn Reson Imaging. 2017 05;45(5):1464-1475. Pubmedid: 27649481. Pmcid: PMC5538355.
  • Navi BB, Parikh NS, Lerario MP, Merkler AE, Lappin RI, Fahimi J, Iadecola C, Kamel H. Risk of Intracerebral Hemorrhage after Emergency Department Discharges for Hypertension. J Stroke Cerebrovasc Dis. 2016 Jul;25(7):1683-1687. Pubmedid: 27068776. Pmcid: PMC4912410.
  • Parikh NS, Cool J, Karas MG, Boehme AK, Kamel H. Stroke Risk and Mortality in Patients With Ventricular Assist Devices. Stroke. 2016 11;47(11):2702-2706. Pubmedid: 27650070. Pmcid: PMC5079813.
  • Rosenkrantz AB, Parikh N, Kierans AS, Kong MX, Babb JS, Taneja SS, Ream JM. Prostate Cancer Detection Using Computed Very High b-value Diffusion-weighted Imaging: How High Should We Go?. Acad Radiol. 2016 06;23(6):704-711. Pubmedid: 26992738.
  • Parikh N, Ream JM, Zhang HC, Block KT, Chandarana H, Rosenkrantz AB. Performance of simultaneous high temporal resolution quantitative perfusion imaging of bladder tumors and conventional multi-phase urography using a novel free-breathing continuously acquired radial compressed-sensing MRI sequence. Magn Reson Imaging. 2016 06;34(5):694-698. Pubmedid: 26740058. Pmcid: PMC4896486.
  • Kierans A, Parikh N, Chandarana H. Recent Advances in MR Hardware and Software. Radiol Clin North Am. 2015 May;53(3):599-610. Pubmedid: 25953292.
  • Gaing B, Sigmund EE, Huang WC, Babb JS, Parikh NS, Stoffel D, Chandarana H. Subtype differentiation of renal tumors using voxel-based histogram analysis of intravoxel incoherent motion parameters. Invest Radiol. 2015 Mar;50(3):144-152. Pubmedid: 25387050.
  • Parikh N, Friedman KP, Shah SN, Chandarana H. Practical guide for implementing hybrid PET/MR clinical service: lessons learned from our experience. Abdom Imaging. 2015 Aug;40(6):1366-1373. Pubmedid: 25985966. Pmcid: PMC4534342.
  • Parikh N, Morris E, Babb J, Wickstrom M, McMenamy J, Sharma R, Schwartz D, Lifshitz M, Kim D. MDCT diagnosis of acute pulmonary embolism in the emergent setting. Emerg Radiol. 2015 Aug;22(4):379-384. Pubmedid: 25573686.
  • Kis B, El-Haddad G, Sheth RA, Parikh NS, Ganguli S, Shyn PB, Choi J, Brown KT. Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 24(3):1073274817729244. Pubmedid: 28975829. Pmcid: PMC5937250.